Much of the discussion around this year’s NBA All-Star Game has been critical and focused on the lack of effort shown on the court by the stars selected to participate in the annual showcase. It’s ...

The Los Angeles Lakers didn’t make a large splash ahead of the 2026 NBA trade deadline, but they did add a veteran sharpshooter in Luke Kennard, team him up with LeBron James and Luka Doncic. The ...

Pfizer said its experimental obesity drug, which it acquired through Metsera, drove solid weight loss when taken once a month in a mid-stage trial. The data offer early evidence that the injection can ...

DISCLAIMER: This site and the products offered are for entertainment purposes only, and there is no gambling offered on this site. This service is intended for adult audiences. No guarantees are made ...

A new drug developed by Australian researchers has shown promising results in reducing sepsis in a Phase II clinical trial involving 180 patients. The carbohydrate-based treatment works by calming a ...

Semaglutide shows promise in improving liver health and metabolic outcomes in MASH, enhancing steatohepatitis resolution and cardiometabolic measures. A large meta-analysis, published in Diabetology & ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Columbus City Council has amended the mayor's budget proposal to add $2 million for the Columbus Promise. The popular Columbus Promise program sends CCS graduates to Columbus State tuition-free. In an ...

A recent publication in Nature Medicine describes a novel immunotherapy targeting pancreatic cancer that has shown promising results in a first in-human phase 1/2 trial. The TACTOPS trial, which ...

Proteomic mass spectrometry can identify key biomarkers in IPF, aiding in diagnosis and prognosis despite the disease's unpredictability and poor survival rates. Mass spectrometry-based proteomics can ...

Infusion of base-edited CAR7 T cells for T-cell acute lymphoblastic leukemia enabled 82% of patients in a phase I study to achieve a deep remission after receiving the therapy, allowing them to ...